Christopher D. Lao

37.1k citations

121 papers · 8.3k indexed · 4 hit papers · h-index 38

Impact in

Molecular Medicine top 0.5%
- Curcumin's Biomedical Applications
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management

Papers in

Oncology 98
- Cancer Immunotherapy and Biomarkers 70
- CAR-T cell therapy research 54
- Cutaneous Melanoma Detection and Management 19
- Polyomavirus and related diseases 6
Immunology 23
- Immunotherapy and Immune Responses 17

Co-authors: Shane Crotty Danelle S. Eto Dirk Schadendorf Robin Kageyama Youn Soo Choi James Larkin F. Stephen Hodi Dean E. Brenner
Journals: Journal of Clinical Oncology (44 papers)Annals of Oncology (13 papers)Cancer (4 papers)Journal for ImmunoTherapy of Cancer (4 papers)The Lancet Oncology (3 papers)
Partner nations: United States Germany France

In The Last Decade

Christopher D. Lao

114 papers receiving 8.1k citations

Hit Papers

align trajectories log scale

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression 2018 · 449 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Investigation
2018 The Lancet Oncology
2011 Immunity
2006 BMC Complementary and Alternative Medicine

Peers

Countries citing papers authored by Christopher D. Lao

Since Specialization

Citations

This map shows the geographic impact of Christopher D. Lao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher D. Lao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher D. Lao more than expected).

Fields of papers citing papers by Christopher D. Lao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher D. Lao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher D. Lao. The network helps show where Christopher D. Lao may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Christopher D. Lao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher D. Lao Line = papers co-authored together Christopher D. Lao links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma npj Precision Oncology ·Sandip Pravin Patel, O. Demirkiran, Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin Powers, Adrienne I. Victor, Adedayo A. Onitilo, Thaynara Lemos Batista Santos, Naoko Takebe, Fernando Regueras Grande, Christine M. McLeod, Karthikeyan Divyapriya, Elad Sharon, Megan Othus, Brigitte Kohn, Charles D. Blanke, Razelle Kurzrock	2025	1
2	Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study Journal of Clinical Oncology ·Shailender Bhatia, Suzanne L. Topalian, William H. Sharfman, Tim Meyer, Neil Steven, Christopher D. Lao, Lorena Fariñas-Madrid, Lot A. Devriese, Kathleen N. Moore, Robert L. Ferris, Yoshitaka Honma, Ileana Elias, Anjaiah Srirangam, Charlie Garnett‐Benson, Michelle Lee, Paul Nghiem	2025	7
3	Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047 Journal for ImmunoTherapy of Cancer ·Meredith M. Regan, Paolo A. Ascierto, Evan J. Lipson, Nathalia Paniagua, Andriy Moshyk, A. Selvan, Christopher D. Lao, Michael B. Atkins, David F. McDermott, Ravi Potluri, 宮田靖志, V.L. van de Poll-Franse, Georgina V. Long, L. Lachytova, Hussein A. Tawbi, Dirk Schadendorf	2025	0
4	Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204 Journal of Clinical Oncology ·Raymond Y. Huang, Gilbert Youssef, 貴士一ノ瀬, Patrick Y. Wen, Peter Forsyth, F. Stephen Hodi, Kim Margolin, Alain P. Algazi, Omid Hamid, Christopher D. Lao, Marc S. Ernstoff, Stergios J. Moschos, Michael B. Atkins, Michael A. Postow, David A. Reardon, Diederik J. Grootendorst, David Leung, Margarita Askelson, Corey Ritchings, Hussein A. Tawbi	2025	2
5	Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era Cancer Immunology Immunotherapy ·内藤和宏, Qi-An Zhang, Alexi Vasbinder, Leslie A. Fecher, Sarah Yentz, Salim S. Hayek, Christopher D. Lao	2024	0
6	Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC). Journal of Clinical Oncology ·Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher D. Lao, Jean‐Jacques Grob, Flavia Ejzykowicz, Nathalia Paniagua, 満則柳沢, Zheng‐Yi Zhou, إسماعيل صعصاع البديري, Lisa Rosenblatt, Laura McDonald, MM. Lucas, Jair Sindra Virtuoso J onior, Divya Patel, A Fujiwara, Georgina V. Long	2024	0
7	Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047 Journal of Clinical Oncology ·Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, MM. Lucas, Speakers Walter Pearson, Antonella Mazzei, Sonia Dolfi, Georgina V. Long	2024	24
8	First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data Journal of Clinical Oncology ·Georgina V. Long, Evan J. Lipson, F. Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher D. Lao, Jean‐Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk, Itanielly Dantas Silveira Cruz, Zheng‐Yi Zhou, Yiqiao Xin, Nathalia Paniagua, Laura McDonald, N. Hirashima, Jair Sindra Virtuoso J onior, Divya Patel, A Fujiwara, Hussein A. Tawbi, Dirk Schadendorf	2024	20
9	LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma Annals of Oncology ·John O. Larkin, (unknown), L. L., Piotr Rutkowski, A. Ryley, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Paola Queirolo, Кутепова Е. А. Шаталов Р. Б., Wang Mengwu, Andrew Hill, Iván Márquez‐Rodas, John B.A.G. Haanen, Forrest C Ward, Margarita Askelson, F. Stephen Hodi, Jedd D. Wolchok	2024	2
10	Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years. Journal of Clinical Oncology ·Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, MM. Lucas, Speakers Walter Pearson, Antonella Mazzei, Sonia Dolfi, Georgina V. Long	2024	7
11	Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067. Journal of Clinical Oncology ·F. Stephen Hodi, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, Piotr Rutkowski, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Paola Queirolo, Michael Smylie, Marcus O. Butler, Andrew Hill, Iván Márquez‐Rodas, Corey Ritchings, A Fujiwara, Peter Wang, Jedd D. Wolchok, James Larkin	2023	0
12	Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. Journal of Clinical Oncology ·Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, MM. Lucas, Speakers Walter Pearson, R. Batterson, Sonia Dolfi, Georgina V. Long	2023	7
13	Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial European Journal of Cancer ·Dirk Schadendorf, Hussein A. Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Jean‐Jacques Grob, Andriy Moshyk, Jennifer Lord‐Bessen, Melissa Hamilton, Shien Guo, Ling Shi, N. Hirashima, Georgina V. Long	2023	9
14	1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204 Annals of Oncology ·Raymond Y. Huang, J Smithson, Matt C. Enkema, Patrick Y. Wen, Peter Forsyth, F. Stephen Hodi, Kim Margolin, Alain P. Algazi, Omid Hamid, Christopher D. Lao, Marc S. Ernstoff, Stergios J. Moschos, Michael B. Atkins, Michael A. Postow, David A. Reardon, Diederik J. Grootendorst, Margarita Askelson, Corey Ritchings, Hussein A. Tawbi	2023	1
15	LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801 Annals of Oncology ·Sapna P. Patel, Megan Othus, Paul Wright, John Hyngstrom, Christopher D. Lao, Yaya Melsul, Sunandana Chandra, Kari Kendra, Craig Devoe, Aparna Hegde, Ankit Mangla, Michael Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Elad Sharon, Larissa A. Korde, James Moon, Vernon K. Sondak, Antoni Ribas, Víctor G. Prieto	2023	7
16	1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047 Annals of Oncology ·F. Stephen Hodi, Hussein A. Tawbi, Evan J. Lipson, Dirk Schadendorf, P.A. Ascierto, Luis Matamala, Eric Gutierrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, Laurence Toms, Gyanendra Karki, D. Gareth Jones, Georgina V. Long	2021	4
17	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma Journal for ImmunoTherapy of Cancer ·Joseph I. Clark, Jatinder Singh, Marc S. Ernstoff, Christopher D. Lao, Lawrence E. Flaherty, Theodore F. Logan, Brendan D. Curti, Sanjiv S. Agarwala, Bret Taback, Lee D. Cranmer, Jose Lutzky, Elovskiĭ Ov, Sandra Aung, David H. Lawson	2018	13
18	Features Predicting Sentinel Lymph Node Positivity in Merkel Cell Carcinoma Journal of Clinical Oncology ·Jennifer Schwartz, Kent A. Griffith, Lori Lowe, Sandra L. Wong, Scott A. McLean, Douglas R. Fullen, Christopher D. Lao, James A. Hayman, Carol R. Bradford, Riley S. Rees, Timothy M. Johnson, Christopher K. Bichakjian	2011	114
19	IL-21 and IL-6 Are Critical for Different Aspects of B Cell Immunity and Redundantly Induce Optimal Follicular Helper CD4 T Cell (Tfh) Differentiation PLoS ONE ·Danelle S. Eto, Christopher D. Lao, Daniel DiToro, Burton E. Barnett, 吉川清, Robin Kageyama, Isharat Yusuf, Shane Crotty	2011	423
20	Strategies for prevention of colorectal cancer: Pharmaceutical and nutritional interventions Current Treatment Options in Oncology ·Christopher D. Lao, Dean E. Brenner	2004	7

About Christopher D. Lao

Christopher D. Lao is a scholar working on Oncology, Immunology, Molecular Biology, Genetics and Ophthalmology, having authored 121 papers that have together received 8.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (70 papers), CAR-T cell therapy research (54 papers), Melanoma and MAPK Pathways (46 papers), Cutaneous Melanoma Detection and Management (19 papers), Immunotherapy and Immune Responses (17 papers), Brain Metastases and Treatment (13 papers), Glioma Diagnosis and Treatment (6 papers) and Polyomavirus and related diseases (6 papers). The work is most often cited by research in Molecular Medicine (943 citations), Oncology (4.5k citations), Immunology (3.1k citations), Dermatology (313 citations) and Genetics (358 citations). Christopher D. Lao has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Shane Crotty, Danelle S. Eto, Dirk Schadendorf, Robin Kageyama, Youn Soo Choi, James Larkin, F. Stephen Hodi, Dean E. Brenner, Jedd D. Wolchok and Daniel P. Normolle. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, Journal for ImmunoTherapy of Cancer and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact